https://www.pharmaradar360.com/article/31c65661d7569975PharmaRadar360en2026-04-28T11:00:00.000ZBenitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meetinghttps://www.pharmaradar360.com/article/0234acd6340e897bPharmaRadar360en2026-04-28T10:49:20.000ZClinical investigations for medical deviceshttps://www.pharmaradar360.com/article/af2c1914c7250528PharmaRadar360en2026-04-28T10:45:00.000ZMerck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Strokehttps://www.pharmaradar360.com/article/0caf145164d598d5PharmaRadar360en2026-04-28T10:00:11.000ZClass 2 Medicines Recall: Amarox Limited, Sertraline 100mg film-coated tablets, EL(26)A/22https://www.pharmaradar360.com/article/fef0238bf3a8443fPharmaRadar360en2026-04-28T09:40:57.000ZΓενόσημα Μαρτίου 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/23227cfb6eda5d1fPharmaRadar360en2026-04-28T09:30:22.000ZCuidar de las personas, construir prevenciónhttps://www.pharmaradar360.com/article/39d65b206f64d674PharmaRadar360en2026-04-28T09:07:38.000ZΑνάκληση των παρτίδων του συνημμένου πίνακα του Ιατροτεχνολογικου προϊόντος, MDD Class IIΙ, 16F Dual—Valved Splittable Sheath Introducerhttps://www.pharmaradar360.com/article/b73bf4319d4c3f39PharmaRadar360en2026-04-28T08:55:15.000ZTransparency data: MHRA Performance Datahttps://www.pharmaradar360.com/article/03acf7e7b84c8e3bPharmaRadar360en2026-04-28T08:30:01.000ZCorporate report: MHRA Results and Forecast 2025/26; 2026/27https://www.pharmaradar360.com/article/b900ea4dd2d27af0PharmaRadar360en2026-04-28T08:27:20.000ZField Safety Notices: 20 to 24 April 2026https://www.pharmaradar360.com/article/09ee7de185d8aa17PharmaRadar360en2026-04-28T08:23:31.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/b04bf8ed33f54042PharmaRadar360en2026-04-28T08:00:00.000ZMedtronic announces CE Mark for Stealth AXiS™ surgical systemhttps://www.pharmaradar360.com/article/9012c0476fb7d655PharmaRadar360en2026-04-28T00:00:00.000ZU.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutationshttps://www.pharmaradar360.com/article/fb06626cb5848656PharmaRadar360en2026-04-28T00:00:00.000ZTaiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Developmenthttps://www.pharmaradar360.com/article/f4534ddf982343f6PharmaRadar360en2026-04-28T00:00:00.000ZShop — Petro's Chili & Chips™https://www.pharmaradar360.com/article/72f10f306250b20dPharmaRadar360en2026-04-28T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/f6c87338842820dePharmaRadar360en2026-04-28T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/1b154f19c8c12d76PharmaRadar360en2026-04-28T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/8db3175e3e4e6db2PharmaRadar360en2026-04-28T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/e7c20b682b129502PharmaRadar360en2026-04-28T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/3a4b22402cc1657bPharmaRadar360en2026-04-28T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/d78495986411b489PharmaRadar360en2026-04-28T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/9e4a5486e3b1f218PharmaRadar360en2026-04-28T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/f5af9b1fe65568f7PharmaRadar360en2026-04-28T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/53799a6cb4a0623aPharmaRadar360en2026-04-28T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/9d192bcc0b34b932PharmaRadar360en2026-04-28T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/9af0fe455b652f6aPharmaRadar360en2026-04-28T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/76f17f4d14f6a08ePharmaRadar360en2026-04-28T00:00:00.000Z6203https://www.pharmaradar360.com/article/4be0694edf92cc2cPharmaRadar360en2026-04-28T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/29bd596b73b193f2PharmaRadar360en2026-04-27T23:01:01.000ZInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelineshttps://www.pharmaradar360.com/article/a6862dc7309468e2PharmaRadar360en2026-04-27T23:01:01.000ZClinical trials for medicines: non-investigational medicinal productshttps://www.pharmaradar360.com/article/b3597069306f2b3bPharmaRadar360en2026-04-27T23:01:01.000ZClinical trials for medicines: good manufacturing practice and radiopharmaceutical investigational medicinal productshttps://www.pharmaradar360.com/article/a76f75508aeb9605PharmaRadar360en2026-04-27T23:01:01.000ZGuidance: Clinical Trials Regulations enforcement provisionshttps://www.pharmaradar360.com/article/da56f4ec834b93afPharmaRadar360en2026-04-27T23:01:01.000ZGuidance: Clinical trials for medicines: roles and responsibilitieshttps://www.pharmaradar360.com/article/cb11560279c42d6bPharmaRadar360en2026-04-27T23:01:01.000ZGuidance: Clinical trials for medicines: Archiving and retention of clinical trial recordshttps://www.pharmaradar360.com/article/664451feb5b37f3ePharmaRadar360en2026-04-27T23:01:00.000ZClinical trials for medicines: notifiable trialshttps://www.pharmaradar360.com/article/cf9746c41f4528a5PharmaRadar360en2026-04-27T23:01:00.000ZClinical trials for medicines: labellinghttps://www.pharmaradar360.com/article/a12171476184f39cPharmaRadar360en2026-04-27T23:01:00.000ZClinical trials for medicines: Good clinical practice inspectionshttps://www.pharmaradar360.com/article/45aaaec4dd9b9189PharmaRadar360en2026-04-27T23:01:00.000ZGuidance: Clinical trials for medicines: International Council for Harmonisation (ICH) annotationshttps://www.pharmaradar360.com/article/013df3e7c83daad6PharmaRadar360en2026-04-27T23:01:00.000ZGuidance: Clinical trials for medicines: Notification of Serious Breaches of GCP or the trial protocolhttps://www.pharmaradar360.com/article/cdd8299e99c8a32dPharmaRadar360en2026-04-27T23:01:00.000ZGuidance: Clinical trials for medicines: Declaration of Helsinki and Clinical Trial Regulations alignmenthttps://www.pharmaradar360.com/article/301195f612f311faPharmaRadar360en2026-04-27T20:13:16.000ZLeading the Cut: 4 Organizations Take on Site Training Reductionhttps://www.pharmaradar360.com/article/e9cc65bf1db4a7dcPharmaRadar360en2026-04-27T19:59:58.000ZMAb-based immunosuppressant supports crucial diabetes cell transplantshttps://www.pharmaradar360.com/article/cf2f9337322793fdPharmaRadar360en2026-04-27T16:00:00.000ZUS legislative reforms needed to make biosimilars competitivehttps://www.pharmaradar360.com/article/5eb54e168c35bad1PharmaRadar360en2026-04-27T12:47:08.000ZAdial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Programhttps://www.pharmaradar360.com/article/abc3282e65ac0345PharmaRadar360en2026-04-27T12:40:37.000ZJazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEAhttps://www.pharmaradar360.com/article/359f71439936dac7PharmaRadar360en2026-04-27T12:05:00.000ZAbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Diseasehttps://www.pharmaradar360.com/article/91ac59383ecf6955PharmaRadar360en2026-04-27T12:03:24.000ZΝέα ΣΥΦΑ 1ου Τριμήνου 2026 _ Τιμολόγηση Φαρμακευτικών Προϊόντωνhttps://www.pharmaradar360.com/article/1328f12328d25d80PharmaRadar360en2026-04-27T12:00:00.000ZGSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASHhttps://www.pharmaradar360.com/article/14e82e4e2dc71444PharmaRadar360en2026-04-27T11:49:01.000ZCORMEDIX THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE III RESPECT TRIAL ASSESSING REZZAYO® FOR THE PROPHYLAXIS OF INVASIVE FUNGAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTShttps://www.pharmaradar360.com/article/63942e363e7d3d45PharmaRadar360en2026-04-27T11:33:03.000ZNervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officerhttps://www.pharmaradar360.com/article/1996c546fad144afPharmaRadar360en2026-04-27T11:28:58.000ZBoletín sobre Productos Sanitarios. Enero-marzo 2026https://www.pharmaradar360.com/article/0e6a59b5912c0800PharmaRadar360en2026-04-27T10:45:00.000ZLilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia verahttps://www.pharmaradar360.com/article/13870ee8e47ff13dPharmaRadar360en2026-04-27T10:39:33.000ZACRP 2026 Panelists Encourage Attendees to “Embrace the Now, Ignite What’s Next”https://www.pharmaradar360.com/article/068b74cebc797047PharmaRadar360en2026-04-27T09:35:23.000ZKOMENTARZ z okazji Światowego Dnia Własności Intelektualnej. prof. Rafał Sikorski, Uniwersytet im. Adama Mickiewicza w Poznaniuhttps://www.pharmaradar360.com/article/80f719e55bb0a4a2PharmaRadar360en2026-04-27T09:33:19.000ZΓενόσημα Φεβρουάριος 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/0dc848fc3b8cd966PharmaRadar360en2026-04-27T08:40:20.000ZLa AEMPS informa del cese de comercialización, retirada del mercado y recuperación de la tinta para tatuaje Dynamic Candy Apple Redhttps://www.pharmaradar360.com/article/c27e20b58bbef60fPharmaRadar360en2026-04-27T07:46:40.000ZAttention aux confusions entre flaconshttps://www.pharmaradar360.com/article/813aae91d272993ePharmaRadar360en2026-04-27T07:00:00.000ZTESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigationhttps://www.pharmaradar360.com/article/ddde03a392de8681PharmaRadar360en2026-04-27T06:55:59.000ZJake Birecki Makes Space for Passion, Purpose and Playhttps://www.pharmaradar360.com/article/ac9f9c8c6c3d257dPharmaRadar360en2026-04-27T06:31:00.000ZFinancial Results of Astellas for FY2025https://www.pharmaradar360.com/article/e7c215493f02a97aPharmaRadar360en2026-04-27T06:30:00.000ZNotice Regarding Impairment Loss and Extraordinary Losses in Non-consolidated Financial Results(J-GAAP)https://www.pharmaradar360.com/article/e8a84c2c8afebd89PharmaRadar360en2026-04-27T06:30:00.000ZNotice of Nominees for Directorshttps://www.pharmaradar360.com/article/4d92c6974eb992b2PharmaRadar360en2026-04-27T06:30:00.000ZAstellas Announces Personnel Changehttps://www.pharmaradar360.com/article/36c516decf75d318PharmaRadar360en2026-04-27T03:00:00.000Z[ANZEN]PMDA Medical Safety Information: Use of Insulin-Specific Syringe- Incorrect dose may cause serious adverse health effects- postedhttps://www.pharmaradar360.com/article/81ba7e827d5a7f33PharmaRadar360en2026-04-27T03:00:00.000Z[YAKKYOKUKATA]Implementation of PDG harmonized texts into Japanese Pharmacopoeia (General Chapters) updatedhttps://www.pharmaradar360.com/article/80547f3614741d8dPharmaRadar360en2026-04-27T03:00:00.000Z[YAKKYOKUKATA]Implementation of PDG harmonized texts into Japanese Pharmacopoeia (Monographs) updatedhttps://www.pharmaradar360.com/article/e4db59030afe0b65PharmaRadar360en2026-04-27T03:00:00.000Z[KOKUSAI]Information on PMDA Asia Office updatedhttps://www.pharmaradar360.com/article/da329d28cc7916cePharmaRadar360en2026-04-27T02:30:00.000ZNotice regarding Withdrawal of Shelf Registration Statement for Issuance of New Shareshttps://www.pharmaradar360.com/article/a22fdef6636ca425PharmaRadar360en2026-04-27T00:00:00.000ZThe Do's and Don'ts of Wearing Weighted Vests